Alirezaei Amirhesam, Fazeli Seyed Amirhossein, Shafiei Meysam, Miladipour Amirhossein
Chronic Kidney Disease Research Center, Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Iran J Kidney Dis. 2022 Jul;16(4):259-265.
SARS-CoV-2 infection have been reported to have a greater mortality rate in adults receiving dialysis, as compared to general population. Hence, vaccination is very important in this vulnerable population group, in order to achieve an acceptable level of immunity. The aim of this study was to compare the level of anti-SARS-CoV-2 anti-spike protein receptor-binding domain IgG neutralizing antibody before and after vaccination with two doses of Sinopharm® vaccine, in patients undergoing hemodialysis.
Ninety patients on maintenance in-center hemodialysis received two doses of Sinopharm® COVID-19 vaccine with an interval of about 28 days. Anti-SARS-CoV-2 anti-spike protein receptor-binding domain IgG (Anti-RBD) neutralizing antibody was measured with an ELISA kit. All statistical analyses were performed by SPSS-26 software.
The absolute mean (± SE) change in antibody titer following full-scheduled vaccination was 8.98 ± 1.49 µg/mL. The rate of seroconversion was 31.1% after two doses of vaccine. In addition, the rate of seroconversion was higher in those with a history of COVID-19 than in those without a history of COVID-19.
The administration of booster doses, doubling of the dose in each episode of vaccination schedule as well as combination of different vaccine platforms are recommended to increase COVID-19 vaccine efficacy in hemodialysis patients. DOI: 10.52547/ijkd.7024.
据报道，与普通人群相比，接受透析的成年人感染新冠病毒后的死亡率更高。因此，为了达到可接受的免疫水平，疫苗接种在这一弱势群体中非常重要。本研究的目的是比较接受血液透析的患者接种两剂国药疫苗前后抗新冠病毒刺突蛋白受体结合域IgG中和抗体的水平。
90名维持性中心血液透析患者接受了两剂国药新冠疫苗，间隔约28天。使用酶联免疫吸附测定试剂盒测量抗新冠病毒刺突蛋白受体结合域IgG（抗RBD）中和抗体。所有统计分析均使用SPSS-26软件进行。
全程接种疫苗后抗体滴度的绝对平均（±标准误）变化为8.98±1.49μg/mL。两剂疫苗接种后的血清转化率为31.1%。此外，有新冠病毒感染史的患者血清转化率高于无新冠病毒感染史的患者。
建议增加加强剂量、在每次接种计划中使剂量加倍以及联合使用不同的疫苗平台，以提高血液透析患者的新冠疫苗效力。DOI: 10.52547/ijkd.7024。
